Colrain Capital’s AbbVie ABBV Stock Holding History

Colrain Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.3M	Buy	25,047 +92	+0.4%	+$19.8K	2.13%	18
2026 Q1	$5.43M	Buy	24,955 +3,540	+17%	+$785K	2.1%	18
2025 Q4	$4.89M	Sell	21,415 -3,405	-14%	-$776K	2.69%	17
2025 Q3	$5.75M	Buy	24,820 +6,320	+34%	+$1.29M	3.27%	16
2025 Q2	$3.43M	Hold	18,500	–	–	2.65%	18
2025 Q1	$3.88M	Buy	18,500 +3,000	+19%	+$583K	3.31%	13
2024 Q4	$2.75M	Buy	+15,500	New	+$2.85M	2.7%	17
2022 Q3	$3.05M	Hold	22,750	–	–	5.09%	6
2022 Q2	$3.48M	Sell	22,750 -2,800	-11%	-$428K	5.45%	6
2022 Q1	$4.14M	Hold	25,550	–	–	5.78%	5
2021 Q4	$3.46M	Buy	25,550 +1,000	+4%	+$118K	4.16%	7
2021 Q3	$2.65M	Buy	24,550 +3,000	+14%	+$343K	4.96%	9
2021 Q2	$2.43M	Sell	21,550 -19,712	-48%	-$2.22M	4.37%	11
2021 Q1	$4.44M	Buy	41,262 +18,550	+82%	+$1.98M	4.58%	12
2020 Q4	$2.43M	Hold	22,712	–	–	4.94%	11
2020 Q3	$1.99M	Sell	22,712 -3,891	-15%	-$366K	4.8%	11
2020 Q2	$2.61M	Sell	26,603 -2,832	-10%	-$249K	5.73%	8
2020 Q1	$2.24M	Sell	29,435 -5,300	-15%	-$451K	4.21%	12
2019 Q4	$3.08M	Sell	34,735 -2,250	-6%	-$187K	3.22%	13
2019 Q3	$2.8M	Buy	36,985 +15,725	+74%	+$1.08M	3.08%	15
2019 Q2	$1.55M	Buy	21,260 +16,510	+348%	+$1.3M	1.74%	21
2019 Q1	$383K	Sell	4,750 -2,500	-34%	-$205K	0.45%	29
2018 Q4	$668K	Hold	7,250	–	–	0.87%	24
2018 Q3	$686K	Hold	7,250	–	–	0.73%	27
2018 Q2	$672K	Hold	7,250	–	–	0.79%	28
2018 Q1	$686K	Hold	7,250	–	–	0.73%	28
2017 Q4	$701K	Sell	7,250 -258	-3%	-$24.3K	0.58%	30
2017 Q3	$667K	Sell	7,508 -2,000	-21%	-$152K	0.31%	41
2017 Q2	$689K	Sell	9,508 -5,350	-36%	-$360K	0.28%	43
2017 Q1	$968K	Sell	14,858 -3,992	-21%	-$251K	0.29%	55
2016 Q4	$1.18M	Sell	18,850 -400	-2%	-$24.4K	0.25%	70
2016 Q3	$1.21M	Sell	19,250 -3,000	-13%	-$194K	0.27%	55
2016 Q2	$1.38M	Sell	22,250 -5,350	-19%	-$326K	0.27%	52
2016 Q1	$1.58M	Sell	27,600 -87,900	-76%	-$4.9M	0.27%	51
2015 Q4	$6.84M	Sell	115,500 -16,000	-12%	-$922K	0.69%	35
2015 Q3	$7.16M	Sell	131,500 -28,771	-18%	-$1.87M	0.75%	33
2015 Q2	$10.8M	Sell	160,271 -56,500	-26%	-$3.69M	0.95%	32
2015 Q1	$12.7M	Sell	216,771 -32,292	-13%	-$1.95M	1.06%	30
2014 Q4	$16.3M	Sell	249,063 -32,000	-11%	-$2.02M	1.26%	30
2014 Q3	$16.2M	Sell	281,063 -46,786	-14%	-$2.6M	1.21%	29
2014 Q2	$18.5M	Sell	327,849 -24,304	-7%	-$1.28M	1.33%	27
2014 Q1	$18.1M	Sell	352,153 -47,486	-12%	-$2.4M	1.35%	26
2013 Q4	$21.1M	Sell	399,639 -43,700	-10%	-$2.15M	1.46%	26
2013 Q3	$19.8M	Sell	443,339 -62,800	-12%	-$2.78M	1.48%	24
2013 Q2	$20.9M	Buy	+506,139	New	+$22.1M	1.53%	23

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Colrain Capital's ABBV Position: Q2 2026 in Review

Colrain Capital increased its AbbVie (ABBV) stake by 0.37% in Q2 2026, buying an estimated $19.8K and bringing the position to 25,047 shares worth $6.3M. The position accounts for 2.13% of the portfolio, ranked #18.

Colrain Capital first reported a position in ABBV in Q2 2013 and has held it in 45 quarters since. The position peaked at $21.1M in Q4 2013. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Colrain Capital held 25,047 shares of AbbVie worth $6.3M as of Q2 2026.
Colrain Capital bought 92 AbbVie shares in Q2 2026, an estimated $19.8K.
AbbVie made up 2.13% of Colrain Capital's portfolio in Q2 2026, its #18 holding.
Colrain Capital first reported a position in AbbVie in Q2 2013 and has held it in 45 quarters since.
Colrain Capital's AbbVie position peaked at $21.1M in Q4 2013.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Colrain Capital's 13F filing for Q2 2026, filed 5 Aug 2026.